Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions
Influenza, HumanAcute Respiratory InfectionViral InfectionCommon Cold
Interventions
DRUG

Ingavirin

Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.

DRUG

Placebo oral capsule

Placebo, capsules daily for 5 days.

Trial Locations (11)

62028

Pediatrician City Hospital number 11, Yekaterinburg

119991

I.M. Sechenov First Moscow State Medical University, Moscow

150000

"GBOU VPO Yaroslavl State Medical University of Ministry of Health of Russian Federation", Yaroslavl

344022

Rostov State Medical University, Rostov-on-Don

344065

Pediatrics outpatient clinic number 4 of Rostov-na-Donu, Rostov-on-Don

410012

Saratov State Medical University named after V. I. Razumovsky, Saratov

420012

"GBOU VPO Kazan State Medical University of Ministry of Health of Russian Federation", Kazan'

430005

Ogarev Mordovia State University, Saransk

614066

City Pediatric Outpatient Clinic number 5, Perm

630091

Novosibirsk State Medical University, Novosibirsk

660022

Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky, Krasnoyarsk

All Listed Sponsors
collaborator

Atlant Clinical Ltd.

OTHER

lead

Valenta Pharm JSC

INDUSTRY

NCT03191097 - Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o. | Biotech Hunter | Biotech Hunter